Metformin HCl API
Type 2 Diabetes
Key Facts
About Vistin Pharma
Vistin Pharma is a publicly traded, pure-play manufacturer of Metformin API, leveraging over 50 years of production heritage from its Norwegian facilities. The company has established itself as a reliable, high-quality supplier to a diverse global client base, including big pharma and generics manufacturers, with its products sold in over 100 countries. Its strategic focus is on doubling its production capacity to over 7,000 MT/year to capture a larger share of the growing metformin market while emphasizing sustainable operations and maintaining its reputation for a nitrosamine-free product. Vistin's vision is to balance business growth with a commitment to having no negative impact on the environment, people, and local communities.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Tirzepatide (Mounjaro) | Eli Lilly | Approved |
| Orforglipron | Eli Lilly | Phase 3 |
| Trulicity (dulaglutide) | Eli Lilly | Approved |
| Forxiga | AstraZeneca | Approved |
| siRNA GalXC-GYS2 | Novo Nordisk | Phase 1 |
| Amylin/semaglutide combination | Novo Nordisk | Phase 3 |
| Lipaglyn | Zydus Lifesciences | Approved |
| LBS-009 | Belite Bio | Preclinical |
| Jentadueto (Linagliptin/Metformin) | Yuhan | Approved |
| Nesina (Alogliptin) | Yuhan | Approved |
| Metformin & Combinations | Ipca Laboratories | Commercial |
| GSBR-1290 | Structure Therapeutics | Phase 2 |